Welcome to our dedicated page for Proto Labs SEC filings (Ticker: PRLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Proto Labs, Inc. filings document the regulatory record for an NYSE-listed digital manufacturing company that produces custom parts for prototyping, testing, bridge production, short-run production, and end-use applications. Its SEC disclosures cover operating results, revenue by service activity, non-GAAP measures, cash-flow commentary, and business updates related to CNC machining, digital platforms, and manufacturing capacity.
PRLB filings also include Form 8-K material-event reports for earnings releases and executive leadership changes, amendments to previously furnished results information, and proxy materials covering board matters, executive compensation, equity awards, shareholder voting items, and governance. The company’s filings identify its common stock under the PRLB ticker on the New York Stock Exchange.
Disciplined Growth Investors, Inc. filed an amended Schedule 13G reporting its ownership in Proto Labs Inc12/31/2025, it beneficially owned 2,673,729 shares of Proto Labs common stock, representing 11.3% of the class.
The firm has sole voting power over 2,398,250 shares and sole dispositive power over 2,673,729 shares, with no shared voting or dispositive power. It certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Proto Labs.
Proto Labs Chief Operations Officer Michael R. Kenison reported a tax-related share withholding transaction. On 02/10/2026, 2,684 shares of common stock were disposed of at $53.18 per share to cover tax obligations, leaving him with 31,842 shares of Proto Labs common stock held directly.
Proto Labs Inc. Chief Financial Officer Daniel Schumacher reported routine equity compensation activity. On February 11, 2026, he exercised 3,135 employee stock options at an exercise price of $33.84 per share, receiving the same number of common shares and holding 43,971 shares directly afterward.
On February 10, 2026, 6,809 common shares were withheld at $53.18 per share to satisfy the exercise price or tax liabilities related to equity awards. All transactions are reported as direct ownership, and the option was noted as fully vested.
Proto Labs Inc. executive stock sale disclosed
Proto Labs Inc. Chief Operations Officer Michael R. Kenison reported selling 2,500 shares of common stock on February 6, 2026 at $60 per share. After this planned trade, he beneficially owns 34,526 shares of Proto Labs common stock.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan that Mr. Kenison adopted on August 15, 2025, which is designed to allow insiders to sell shares according to predetermined instructions.
This notice states that an insider plans to sell 7,500 shares of common stock of the issuer under Rule 144. The planned sale, through Morgan Stanley Smith Barney, has an aggregate market value of $393,600 based on the filing and is expected around February 6, 2026 on the NYSE. The filing notes that there were 23,678,745 common shares outstanding at the time referenced.
The 7,500 shares to be sold were acquired as restricted stock units from the issuer on May 20, 2020. In the past three months, Rule 10b5-1 sales for Michael Kenison included a prior sale of 3,048 common shares on November 25, 2025 for gross proceeds of $152,930.66.
Proto Labs, Inc. filed an amended current report to correct a guidance figure in its previously issued outlook. The amendment clarifies that the company’s GAAP diluted earnings per share guidance range for the first quarter of 2026 is $0.18 to $0.26, instead of the $0.17 to $0.25 range originally described in the attached press release. No other aspects of the earlier report or the press release were changed, and the correction is described as a scrivener’s error.
Proto Labs, Inc. reported record fourth-quarter 2025 revenue of $136.5 million, up 12.1% from a year ago, and returned to profitability with net income of $6.0 million, or $0.25 per diluted share, versus a small loss last year. Non-GAAP net income was $10.7 million, or $0.44 per diluted share.
For full year 2025, revenue reached a record $533.1 million, a 6.4% increase, with net income rising to $21.2 million, or $0.88 per diluted share. CNC Machining led growth, while 3D Printing and Injection Molding declined slightly. Adjusted EBITDA was $78.1 million, a 14.7% margin, and operating cash flow was $74.5 million, supporting a year-end cash and investments balance of $142.4 million.
Management highlighted four strategic pillars—elevating customer experience, accelerating innovation, expanding production, and driving operational efficiency—and issued 2026 guidance calling for 6% to 8% revenue growth. For Q1 2026, the company expects revenue of $130.0 million to $138.0 million and diluted EPS of $0.17 to $0.25, or $0.36 to $0.44 on a non-GAAP basis.
Proto Labs, Inc. Chief Operations Officer Michael R. Kenison reported the acquisition of 8,128 shares of Proto Labs common stock on January 29, 2026, at a reported price of $0 per share. Following this transaction, he beneficially owns 37,026 shares of Proto Labs common stock in direct ownership, as disclosed in this Form 4 insider filing.
Proto Labs Inc. Chief Financial Officer Daniel Schumacher reported acquiring additional company stock. On January 29, 2026, he acquired 20,686 shares of Proto Labs common stock at a reported price of $0 per share. Following this transaction, he directly beneficially owned 47,645 shares of Proto Labs common stock, as disclosed in this Form 4 insider filing.
An affiliated holder of PRLB has filed a notice of proposed sale of restricted or control securities under Rule 144. The person plans to sell 368 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an approximate sale date of 01/16/2026 on the NYSE. These 368 common shares were acquired on 05/15/2025 through an Employee Stock Purchase Plan from the issuer and paid for in cash.
Over the prior three months, the same seller, Oleg Ryaboy, has reported multiple sales of the issuer’s common stock, including 9,710 shares sold on 11/07/2025 for gross proceeds of 471,629.27 and 7,178 shares sold on 01/15/2026 for gross proceeds of 393,330.00. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.